Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Intravesical gene therapy

12 evidence topics · 8 sources

Detalimogene voraplasmid: investigational non-viral gene therapy, LEGEND pivotal Cohort 1

“Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease.” (opens the source at this quote in a new tab)

“The following efficacy data are based on 120 efficacy-evaluable patients enrolled in Cohort 1 as of the data cutoff date, October 29, 2026.” (opens the source at this quote in a new tab)

“CR at any time of 56% (CI:47%, 65%) (n=120)” (opens the source at this quote in a new tab)

“Landmark 12-month CR rate is 24% (CI: 16%, 33%) (n=110)” (opens the source at this quote in a new tab)

“Median duration of complete response is 10.1 months (CI: 7.5, Not Estimable)” (opens the source at this quote in a new tab)

“Of the 125 patients assessed for safety in Cohort 1, 59% experienced at least one TRAE, which were mainly Grade 1/2 in severity.” (opens the source at this quote in a new tab)

“Only 4% of patients experienced Grade 3 TRAE, with just 2% of patients experiencing a serious TRAE. No Grade 4 or Grade 5 TRAEs were reported.” (opens the source at this quote in a new tab)

“The Company expects to initiate the submission by year-end 2026 and plans to complete the BLA submission in the first half of 2027, with potential FDA approval in 2027.” (opens the source at this quote in a new tab)